Drug Profile
SER 262
Alternative Names: SER262Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Seres Therapeutics
- Class Antibacterials; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for phase-I development in Clostridium-difficile-infections(Prevention) in USA (PO, Capsule)
- 31 Dec 2019 SER 262 is still in phase I trial for Clostridium difficile infections (Prevention) in USA
- 02 Oct 2019 Updated efficacy data from the phase Ib SERES-262-001 trial presented at the ID Week (IDW-2019)